" Leishmania and HIV co-infection: first naturally Leishmania strain presenting decreased susceptibility to Miltefosine, recovered from a patient in Portugal."

Ana Isabel Pinto,Cátia Caldas,Nuno Santarém,Sara Luelmo,Inês Costa,Carlos Martins,Ricardo Monteiro,Sílvia Conde,Raquel Tavares,Anabela Cordeiro da Silva
DOI: https://doi.org/10.1016/j.jiph.2024.03.008
IF: 7.537
2024-03-14
Journal of Infection and Public Health
Abstract:Background In Europe, up to 70% of visceral leishmaniasis (VL) cases occurring in adults living with HIV. People living with HIV with VL co-infection often display persistent parasitemia, requiring chronic intermittent anti- Leishmania therapies. Consequently, frequent VL relapses and higher mortality rates are common in these individuals. As such, it is of paramount importance to understand the reasons for parasite persistence to improve infection management. Methods To outline possible causes for treatment failure in the context of HIV-VL, we followed a person living with HIV-VL co-infection for nine years in a 12-month period. We characterized: HIV-related clinicopathological alterations (CD4 + T counts and viremia) and Leishmania -specific seroreactivity, parasitemia, quantification of pro-inflammatory cytokines upon stimulation and studied a Leishmania clinical isolate recovered during this period. Results The subject presented controlled viremia and low CD4 + counts. The subject remained PCR positive for Leishmania and also seropositive. The cellular response to parasite antigens was erratic. The isolate was identified as the first Leishmania infantum case with evidence of decreased miltefosine susceptibility in Portugal. Conclusion Treatment failure is a multifactorial process driven by host and parasite determinants. Still, the real-time determination of drug susceptibility profiles in clinical isolates is an unexplored resource in the monitoring of VL.
infectious diseases,public, environmental & occupational health
What problem does this paper attempt to address?